Key Players
Competitive Landscape
The competitive field combines an approved biologic manufacturer, peptide developers, topical gene-therapy companies and early-stage regenerative platforms. These groups compete at different regulatory stages, so evidence of complete corneal healing matters more than pipeline breadth alone.
Clinical investment has moved in two directions since 2025: toward lower-frequency peptide drops and sustained local nerve growth factor delivery. TearSolutions initiated a phase 2 Lacripep study planned for 54 participants in June 2026. Krystal Biotech reported continued enrollment in the 60-patient EMERALD-1 registrational study in May 2026. Price remains relevant to access, yet corneal specialists and payers first compare complete healing with dosing burden and post-treatment durability.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| TearSolutions initiated a phase 2 Lacripep study planned for 54 participants in June 2026 after receiving FDA orphan and Fast Track designations. | Specialists need a practical topical option for earlier-stage disease that can support nerve function and epithelial repair. | Peptide candidates are moving from exploratory ocular-surface studies into controlled neurotrophic keratitis trials. | Revenue depends on specialist adoption and payer coverage for a lower-frequency regenerative eye-drop regimen. |
| Krystal Biotech reported continued enrollment in the 60-patient EMERALD-1 registrational study in May 2026 for daily KB801 administration. | Current rhNGF treatment places a heavy daily administration burden on patients and caregivers. | Topical gene delivery is moving toward sustained local NGF expression with patient or caregiver administration. | A successful program could compete on treatment convenience and durable healing across specialist centers. |
| Staidson initiated a 48-participant phase 2 STSP-0902 study in June 2025 for stage 2 and stage 3 neurotrophic keratitis. | Specialists need dosing evidence for a new NGF-modulating topical route across persistent defects and corneal ulcers. | China-based developers are entering controlled phase 2 neurotrophic keratitis studies with multiple dosing arms. | Positive healing data could support domestic specialist adoption and regional licensing for STSP-0902. |
Dompé farmaceutici S.p.A., BRIM Biotechnology, Inc., Claris Biotherapeutics, Inc., 2A Biosciences, Inc., ReGenTree, LLC and Allovision, LLC compete through approval status or differentiated regenerative routes, although no separate corporate development from them is included in this three-row table.
Source: Future Market Insights. Neurotrophic Keratitis Treatment Market and Ophthalmic Biologics Market Reports for 2026-2036.
Dompé and the clinical-stage developers collectively cover approved rhNGF, peptide repair, topical gene delivery, thymosin beta 4, small-molecule neuroregeneration and serum-derived treatment approaches.
Who leads the neurotrophic keratitis treatment market?
Dompé leads on regulatory maturity because Oxervate remains the only FDA-approved drug for neurotrophic keratitis. Krystal Biotech competes through KB801, which is testing sustained local NGF expression in a 60-patient registrational study.
Which suppliers have documented regulatory or clinical qualifications?
Oxervate has FDA approval for neurotrophic keratitis under Dompé farmaceutici S.p.A. TearSolutions holds FDA orphan and Fast Track designations for Lacripep and Krystal's HSV-1 vector has platform technology designation.
Which companies provide disease-modifying topical treatment candidates?
Dompé supplies approved cenegermin for nerve growth factor replacement. TearSolutions, BRIM Biotechnology, Claris Biotherapeutics and ReGenTree develop peptide or biologic drops that target corneal repair. Krystal Biotech uses topical gene delivery to sustain local NGF expression.
Which suppliers serve North America and Europe?
Dompé has approved cenegermin across the United States and European Union. ReGenTree has run phase 3 RGN-259 studies across the United States and several European countries. BRIM Biotechnology and Krystal Biotech currently concentrate their registered neurotrophic keratitis studies in the United States.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Dompé farmaceutici S.p.A. | United States, European Union and Japan | Approved cenegermin 0.002% eye drops for neurotrophic keratitis with six daily doses across an eight-week course. |
| TearSolutions, Inc. | United States clinical development | Lacripep 4 μM peptide eye drops in a 54-participant phase 2 study for stage 1 neurotrophic keratitis. |
| Krystal Biotech, Inc. | United States clinical development | KB801 topical HSV-1 vector for sustained local NGF expression in the 60-patient EMERALD-1 study. |
| ReGenTree, LLC | United States and European clinical development | RGN-259 thymosin beta 4 eye drops in phase 3 studies for stage 2 and stage 3 neurotrophic keratopathy. |
| BRIM Biotechnology, Inc. | United States clinical development with Taiwan-based platform ownership | BRM424 peptide eye drops in a 12-participant phase 2 dose-ranging study for stage 2 and stage 3 disease. |
| Claris Biotherapeutics, Inc. | United States clinical development | CSB-001 ophthalmic solution completed a randomized phase 1/2 study in stage 2 and stage 3 neurotrophic keratitis. |
| 2A Biosciences, Inc. | United States preclinical and regulatory development | Small-molecule serotonin 5-HT2A/2C receptor agonist with FDA orphan designation dated February 2026. |
| Allovision, LLC | United States preclinical and regulatory development | Allogeneic human blood serum with FDA orphan designation for neurotrophic keratitis dated September 2024. |
| Staidson (Beijing) Biopharmaceuticals Co., Ltd. | China clinical development | STSP-0902 ophthalmic solution in a 48-participant phase 2 study for stage 2 and stage 3 neurotrophic keratitis. |
Research Methodology
The companies illustrate market structure rather than a ranking. A company appears only where current official evidence links it to an approved or investigational neurotrophic keratitis treatment. Evidence includes regulator records, clinical-trial registries, company filings and dated company announcements. Regulatory status belongs to the named sponsor or legal entity. The 9.4% rhNGF figure is an FMI segment CAGR for the 2026-2036 forecast period and does not represent company share.
